GSK2586184: Phase IIa data

Top-line data from the double-blind, German and U.K. Phase IIa JAK116679 trial in 66 patients with chronic plaque psoriasis showed that twice-daily 400 mg oral GSK2586184 met the primary endpoint of a greater proportion of patients achieving a PASI 75 response at week 12 vs. placebo. Galapagos and partner GlaxoSmithKline declined to disclose whether the twice-daily 100 and 200 mg doses of GSK2586184 met the endpoint. The most common adverse events reported were headache and nasopharyngitis. GSK, which conducted the trial, said it will review the complete data from all trials with GSK2586184 before determining next steps. ...